×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BLUE – bluebird bio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BLUE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
02:03 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/19
08:07 am
blue
March Biosciences Elects Peter Olagunju as Chair of Board of Directors [Yahoo! Finance]
Low
Report
March Biosciences Elects Peter Olagunju as Chair of Board of Directors [Yahoo! Finance]
12/12
02:03 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/8
12:30 pm
blue
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Medium
Report
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
12/7
12:00 pm
blue
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Medium
Report
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
12/4
04:05 pm
blue
bluebird bio Announces 1-for-20 Reverse Stock Split
High
Report
bluebird bio Announces 1-for-20 Reverse Stock Split
12/4
08:47 am
blue
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
High
Report
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
12/4
02:08 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
11/15
01:19 pm
Reiterates
Sector Perform
Sector Perform
Royal Bank of Canada
Low
Report
-0.2%
11/15
01:19 pm
Reiterates
Sector Perform
Sector Perform
Royal Bank of Canada
Low
Report
-0.2%
Date
Time
Symbol
Headline
Impact
12/13
04:05 pm
blue
Form 8-K bluebird bio, Inc. For: Dec 12
High
Report
Form 8-K bluebird bio, Inc. For: Dec 12
12/10
09:51 pm
blue
Form 144 bluebird bio, Inc. Filed by: Colvin Richard A
Medium
Report
Form 144 bluebird bio, Inc. Filed by: Colvin Richard A
12/10
09:40 pm
blue
Form 144 bluebird bio, Inc. Filed by: Obenshain Andrew
Medium
Report
Form 144 bluebird bio, Inc. Filed by: Obenshain Andrew
12/4
04:06 pm
blue
Form 8-K bluebird bio, Inc. For: Dec 04
High
Report
Form 8-K bluebird bio, Inc. For: Dec 04
11/14
04:44 pm
blue
Form DEFA14A bluebird bio, Inc.
High
Report
Form DEFA14A bluebird bio, Inc.
11/14
04:40 pm
blue
Form SC 13G/A bluebird bio, Inc. Filed by: Alyeska Investment Group, L.P.
High
Report
Form SC 13G/A bluebird bio, Inc. Filed by: Alyeska Investment Group, L.P.
11/14
04:28 pm
blue
Form SC 13G/A bluebird bio, Inc. Filed by: Granahan Investment Management, LLC
High
Report
Form SC 13G/A bluebird bio, Inc. Filed by: Granahan Investment Management, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/10
bluebird bio Inc (NASDAQ: BLUE) had its "hold" rating re-affirmed by analysts at William Blair.
13.2%
4/8 Form 4 bluebird bio, Inc. For: Apr 06 Filed by: Smith-Farrell Joanne 9.3%
2/1 bluebird bio Inc (NASDAQ: BLUE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.1%
6/6 bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding ßA-T87Q-globin gene) Approval 8.1%
12/13 bluebird bio Inc (NASDAQ: BLUE) was upgraded by analysts at Oppenheimer Holdings Inc. to a "buy" rating. They now have a $135.00 price target on the stock. 7.0%
12/23 Form 4 bluebird bio, Inc. For: Dec 19 Filed by: WENTWORTH KORY JAMES 6.1%
6/13 bluebird bio Inc (NASDAQ: BLUE) had its "buy" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $195.00 price target on the stock. 5.5%
5/16 bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ß-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress 4.8%
10/31 Form 8-K bluebird bio, Inc. For: Oct 31 4.6%
6/14 Bluebird CEO defends $1.8 million gene therapy price — 'It's really thinking about it differently' [CNBC] 4.3%
4/8 Form 4 bluebird bio, Inc. For: Apr 06 Filed by: Smith-Farrell Joanne 9.3%
2/1 bluebird bio Inc (NASDAQ: BLUE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.1%
6/6 bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding ßA-T87Q-globin gene) Approval 8.1%
12/13 bluebird bio Inc (NASDAQ: BLUE) was upgraded by analysts at Oppenheimer Holdings Inc. to a "buy" rating. They now have a $135.00 price target on the stock. 7.0%
12/23 Form 4 bluebird bio, Inc. For: Dec 19 Filed by: WENTWORTH KORY JAMES 6.1%
6/13 bluebird bio Inc (NASDAQ: BLUE) had its "buy" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $195.00 price target on the stock. 5.5%
5/16 bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ß-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress 4.8%
10/31 Form 8-K bluebird bio, Inc. For: Oct 31 4.6%
6/14 Bluebird CEO defends $1.8 million gene therapy price — 'It's really thinking about it differently' [CNBC] 4.3%
TOP News Decliners
12/7
bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition
-12.0%
2/18 Form 8-K bluebird bio, Inc. For: Feb 18 -9.7%
10/23 bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh -8.7%
8/21 Form 4 bluebird bio, Inc. For: Aug 20 Filed by: Walsh Jeffrey T. -7.3%
6/18 Maxim turns bullish on Bluebird [Seeking Alpha] -6.8%
4/27 Form DEF 14A bluebird bio, Inc. For: Jun 18 -6.8%
6/7 Form 4 bluebird bio, Inc. For: Jun 05 Filed by: Gregory Philip D -6.4%
8/1 Q2/2019 6/30/2019 EPS -3.550 ZacksConsensus -3.030 ActVsEst (0.520) - Miss -6.1%
6/14 Form 8-K bluebird bio, Inc. For: Jun 14 -5.8%
1/13 Form 8-K bluebird bio, Inc. For: Jan 13 -5.7%
2/18 Form 8-K bluebird bio, Inc. For: Feb 18 -9.7%
10/23 bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh -8.7%
8/21 Form 4 bluebird bio, Inc. For: Aug 20 Filed by: Walsh Jeffrey T. -7.3%
6/18 Maxim turns bullish on Bluebird [Seeking Alpha] -6.8%
4/27 Form DEF 14A bluebird bio, Inc. For: Jun 18 -6.8%
6/7 Form 4 bluebird bio, Inc. For: Jun 05 Filed by: Gregory Philip D -6.4%
8/1 Q2/2019 6/30/2019 EPS -3.550 ZacksConsensus -3.030 ActVsEst (0.520) - Miss -6.1%
6/14 Form 8-K bluebird bio, Inc. For: Jun 14 -5.8%
1/13 Form 8-K bluebird bio, Inc. For: Jan 13 -5.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: